SummitTX Capital L.P. Invests $814,000 in Vera Therapeutics, Inc. $VERA

SummitTX Capital L.P. purchased a new stake in Vera Therapeutics, Inc. (NASDAQ:VERA) during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 20,244 shares of the company’s stock, valued at approximately $814,000.

Several other large investors have also modified their holdings of the business. UBS Group AG lifted its position in Vera Therapeutics by 27.9% during the 4th quarter. UBS Group AG now owns 207,289 shares of the company’s stock valued at $10,497,000 after acquiring an additional 45,214 shares during the period. Vanguard Group Inc. boosted its stake in Vera Therapeutics by 11.9% during the fourth quarter. Vanguard Group Inc. now owns 3,570,401 shares of the company’s stock worth $180,805,000 after acquiring an additional 379,748 shares in the last quarter. Swedbank AB grew its holdings in Vera Therapeutics by 142.4% in the fourth quarter. Swedbank AB now owns 121,200 shares of the company’s stock worth $6,138,000 after purchasing an additional 71,200 shares during the period. AMI Asset Management Corp purchased a new stake in Vera Therapeutics in the fourth quarter worth about $1,444,000. Finally, TimesSquare Capital Management LLC bought a new position in shares of Vera Therapeutics during the fourth quarter valued at approximately $12,785,000. 99.21% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on VERA. Jefferies Financial Group reissued a “buy” rating and issued a $60.00 price target on shares of Vera Therapeutics in a research report on Tuesday, June 2nd. The Goldman Sachs Group reiterated a “buy” rating and set a $90.00 price objective on shares of Vera Therapeutics in a research note on Tuesday, June 2nd. Evercore set a $91.00 target price on Vera Therapeutics in a report on Friday, May 15th. William Blair reissued an “outperform” rating on shares of Vera Therapeutics in a research note on Tuesday, June 2nd. Finally, HC Wainwright raised their price target on Vera Therapeutics from $110.00 to $125.00 and gave the company a “buy” rating in a report on Wednesday, July 8th. Eleven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $84.58.

Insider Activity

In other news, CEO Marshall Fordyce sold 46,250 shares of the company’s stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $42.30, for a total transaction of $1,956,375.00. Following the transaction, the chief executive officer directly owned 151,994 shares of the company’s stock, valued at $6,429,346.20. This represents a 23.33% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 83,250 shares of company stock worth $3,337,770 over the last 90 days. Corporate insiders own 15.90% of the company’s stock.

Vera Therapeutics Trading Up 1.7%

NASDAQ:VERA opened at $33.05 on Friday. The stock has a market cap of $2.37 billion, a price-to-earnings ratio of -5.97 and a beta of 0.92. The company has a quick ratio of 13.64, a current ratio of 13.64 and a debt-to-equity ratio of 0.15. The company’s 50 day moving average price is $36.95 and its 200-day moving average price is $39.68. Vera Therapeutics, Inc. has a 52 week low of $19.07 and a 52 week high of $56.05.

Vera Therapeutics (NASDAQ:VERA) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($1.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.33) by ($0.36). During the same period in the prior year, the firm posted ($0.81) EPS. On average, equities research analysts forecast that Vera Therapeutics, Inc. will post -6.37 earnings per share for the current fiscal year.

Vera Therapeutics Company Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.